{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:01:15Z","timestamp":1792425675592,"version":"4.5.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Neuromyelitis optica spectrum disorders (NMOSD) is a rare autoimmune disorder that causes severe inflammation in the central nervous system (CNS), primarily affecting the optic nerves, spinal cord, and brainstem. Aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) are a diagnostic marker of the disease and play a significant role in its pathogenesis, though the exact mechanism is not yet fully understood. To develop rodent models that best simulate the\n                    <jats:italic>in vivo<\/jats:italic>\n                    pathological and physiological processes of NMOSD, researchers have been continuously exploring how to establish the ideal model. In this process, two key issues arise: 1) how the AQP4 antibody crosses the blood-brain barrier, and 2) the source of the AQP4 antibody. These two factors are critical for the successful development of rodent models of NMOSD. This paper reviews the current state of research on these two aspects.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2024.1423107","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T01:18:06Z","timestamp":1731979086000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Scientific issues with rodent models of neuromyelitis optic spectrum disorders"],"prefix":"10.3389","volume":"15","author":[{"given":"Yusen","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangruyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.616301","article-title":"The emerging role of microglia in neuromyelitis optica","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1742-2094-5-22","article-title":"Neuromyelitis optica pathogenesis and aquaporin 4","volume":"5","author":"Graber","year":"2008","journal-title":"J Neuroinflammation"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2014.06.003","article-title":"Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica","volume":"62","author":"Ratelade","year":"2014","journal-title":"Mol Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2009.11.003","article-title":"Preparing serum for functional complement assays","volume":"352","author":"Lachmann","year":"2010","journal-title":"J Immunol Methods"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027412","article-title":"Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postrema","volume":"6","author":"Ratelade","year":"2011","journal-title":"PloS One"},{"key":"B7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/2051-5960-2-48","article-title":"Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury","volume":"2","author":"Asavapanumas","year":"2014","journal-title":"Acta Neuropathologica Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181a82621","article-title":"A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset","volume":"72","author":"Nishiyama","year":"2009","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti\u2013aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann Neurology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.06.085","article-title":"Neuromyelitis optica: Passive transfer to rats by human immunoglobulin","volume":"386","author":"Kinoshita","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.227298","article-title":"Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1\/M23 isoforms and orthogonal arrays","volume":"286","author":"Crane","year":"2011","journal-title":"J Biol Chem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1204-8","article-title":"Unique neuromyelitis optica pathology produced in na\u00efve rats by intracerebral administration of NMO-IgG","volume":"127","author":"Asavapanumas","year":"2014","journal-title":"Acta Neuropathologica"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-015-0259-2","article-title":"Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody","volume":"3","author":"Kurosawa","year":"2015","journal-title":"Acta Neuropathologica Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/bpa.12793","article-title":"Experimental animal models of aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress and shortcomings","volume":"30","author":"Duan","year":"2020","journal-title":"Brain Pathology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2013.03.001","article-title":"Optic neuritis in neuromyelitis optica","volume":"36","author":"Levin","year":"2013","journal-title":"Prog Retinal Eye Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis","volume":"326","author":"Beck","year":"1992","journal-title":"New Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1742-2094-11-16","article-title":"Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G","volume":"11","author":"Asavapanumas","year":"2014","journal-title":"J Neuroinflammation"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0746-9","article-title":"Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G","volume":"13","author":"Felix","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2013.12.010","article-title":"Sera from patients with seropositive neuromyelitis optica spectral disorders caused the degeneration of rodent optic nerve","volume":"119","author":"Matsumoto","year":"2014","journal-title":"Exp Eye Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-016-0454-0","article-title":"Rescue effects of intravenous immunoglobulin on optic nerve degeneration in a rat model of neuromyelitis optica","volume":"60","author":"Nobuyoshi","year":"2016","journal-title":"Japanese J Ophthalmology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2018.06.011","article-title":"Structural and visual functional deficits in a rat model of neuromyelitis optica spectrum disorders related optic neuritis","volume":"175","author":"Zhang","year":"2018","journal-title":"Exp Eye Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2014.02.011","article-title":"Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59","volume":"53","author":"Zhang","year":"2014","journal-title":"J Autoimmunity"},{"key":"B26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jneuroim.2012.09.010","article-title":"Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid","volume":"254","author":"Asgari","year":"2013","journal-title":"J Neuroimmunology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0577-8","article-title":"Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid","volume":"13","author":"Marignier","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02232-w","article-title":"Anti-AQP4 autoantibodies promote ATP release from astrocytes and induce mechanical pain in rats","volume":"18","author":"Ishikura","year":"2021","journal-title":"J Neuroinflamm"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.129","article-title":"Pain in neuromyelitis optica\u2014prevalence, pathogenesis and therapy","volume":"10","author":"Bradl","year":"2014","journal-title":"Nat Rev Neurology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1471-2377-13-104","article-title":"Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitis","volume":"13","author":"Saini","year":"2013","journal-title":"BMC Neurology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26327","article-title":"RGMa signal in macrophages induces neutrophil-related astrocytopathy in NMO","volume":"91","author":"Iwamoto","year":"2022","journal-title":"Ann Neurology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01438","article-title":"Aquaporin-4 autoantibodies from neuromyelitis optica spectrum disorder patients induce complement-independent immunopathologies in mice","volume":"9","author":"Yick","year":"2018","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2012.02.001","article-title":"Aquaporin-4 autoantibodies cause asymptomatic aquaporin-4 loss and activate astrocytes in mouse","volume":"245","author":"Chan","year":"2012","journal-title":"J Neuroimmunology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00401-011-0824-0","article-title":"Pathogenic T cell responses against aquaporin 4","volume":"122","author":"Pohl","year":"2011","journal-title":"Acta Neuropathologica"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-015-1501-5","article-title":"Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS","volume":"130","author":"Zeka","year":"2015","journal-title":"Acta Neuropathologica"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2051-5960-1-5","article-title":"Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats","volume":"1","author":"Kitic","year":"2013","journal-title":"Acta Neuropathologica Commun"},{"key":"B37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jnen\/nly107","article-title":"Noninvasive, targeted creation of neuromyelitis optica pathology in AQP4-igG seropositive rats by pulsed focused ultrasound","volume":"78","author":"Yao","year":"2019","journal-title":"J Neuropathology Exp Neurology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"102473","DOI":"10.1016\/j.msard.2020.102473","article-title":"Experimental mouse model of NMOSD produced by facilitated brain delivery of NMO-IgG by microbubble-enhanced low-frequency ultrasound in experimental allergic encephalomyelitis mice","volume":"46","author":"Luo","year":"2020","journal-title":"Multiple Sclerosis Related Disord"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-021-00646-x","article-title":"Recombinant myelin oligodendrocyte glycoprotein quality modifies evolution of experimental autoimmune encephalitis in macaques","volume":"101","author":"Stimmer","year":"2021","journal-title":"Lab Invest"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1631-4","article-title":"Multiple sclerosis: experimental models and reality","volume":"133","author":"Lassmann","year":"2017","journal-title":"Acta Neuropathologica"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2022.2084273","article-title":"The role of autophagy-related proteins in the pathogenesis of neuromyelitis optica spectrum disorders","volume":"13","author":"Guo","year":"2022","journal-title":"Bioengineered"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00568-8","article-title":"Hope for patients with neuromyelitis optica spectrum disorders \u2014 from mechanisms to trials","volume":"17","author":"Pittock","year":"2021","journal-title":"Nat Rev Neurology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2306572120","article-title":"T cell deletional tolerance restricts AQP4 but not MOG CNS autoimmunity","volume":"120","author":"Sagan","year":"2023","journal-title":"Proc Natl Acad Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617859114","article-title":"Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4","volume":"113","author":"Sagan","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-016-0355-y","article-title":"Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO\/SD","volume":"4","author":"Zeka","year":"2016","journal-title":"Acta Neuropathologica Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.727750","article-title":"Low Frequency Ultrasound With Injection of NMO-IgG and Complement Produces Lesions Different From Experimental Autoimmune Encephalomyelitis Mice","volume":"12","author":"Xiang","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3390\/pharmaceutics15071896","article-title":"Efficacy and safety of low-intensity pulsed ultrasound-induced blood\u2013retinal barrier opening in mice","volume":"15","author":"Bourdin","year":"2023","journal-title":"Pharmaceutics"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-023-00489-2","article-title":"Breaking barriers: exploring mechanisms behind opening the blood\u2013brain barrier","volume":"20","author":"Stamp","year":"2023","journal-title":"Fluids Barriers CNS"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy010","article-title":"Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica","volume":"141","author":"Wilson","year":"2018","journal-title":"Brain"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz106","article-title":"Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production","volume":"142","author":"Cotzomi","year":"2019","journal-title":"Brain"},{"key":"B51","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/imr.v292.1","article-title":"Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies","volume":"292","author":"Meffre","year":"2019","journal-title":"Immunol Rev"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.3390\/cells10051190","article-title":"B cell activation and escape of tolerance checkpoints: recent insights from studying autoreactive B cells","volume":"10","author":"Bonasia","year":"2021","journal-title":"Cells"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02623-7","article-title":"A novel aquaporin-4-associated optic neuritis rat model with severe pathological and functional manifestations","volume":"19","author":"Morita","year":"2022","journal-title":"J Neuroinflamm"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1950-8","article-title":"Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat","volume":"137","author":"Hillebrand","year":"2019","journal-title":"Acta Neuropathologica"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22551","article-title":"Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Neurology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.161003","article-title":"T follicular helper cells contribute to pathophysiology in a model of neuromyelitis optica spectrum disorders","volume":"8","author":"Yick","year":"2023","journal-title":"JCI Insight"},{"key":"B57","doi-asserted-by":"publisher","first-page":"578109","DOI":"10.1016\/j.jneuroim.2023.578109","article-title":"Intradermal AQP4 peptide immunization induces clinical features of neuromyelitis optica spectrum disorder in mice","volume":"380","author":"Serizawa","year":"2023","journal-title":"J Neuroimmunology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.06.014","article-title":"Rituximab-induced serum sickness: A systematic review","volume":"45","author":"Karmacharya","year":"2015","journal-title":"Semin Arthritis Rheumatism"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00778","article-title":"Pain in NMOSD and MOGAD: A systematic literature review of pathophysiology, symptoms, and current treatment strategies","volume":"11","author":"Asseyer","year":"2020","journal-title":"Front Neurol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514522103","article-title":"Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life","volume":"20","author":"Zhao","year":"2014","journal-title":"Multiple Sclerosis J"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/NXI.0000000000000985","article-title":"Pain, depression, and quality of life in neuromyelitis optica spectrum disorder","volume":"8","author":"Ayzenberg","year":"2021","journal-title":"Neurol Neuroimmunology Neuroinflammation"},{"key":"B63","doi-asserted-by":"publisher","first-page":"35","DOI":"10.31083\/j.fbl2802035","article-title":"Aquaporins and neuropathic pain","volume":"28","author":"Wang","year":"2023","journal-title":"Front Bioscience-Landmark"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520933884","article-title":"Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD","volume":"27","author":"Kunchok","year":"2021","journal-title":"Multiple Sclerosis J"},{"key":"B66","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10067-023-06809-z","article-title":"Nationwide analysis of neuromyelitis optica in systemic lupus erythematosus and Sjogren\u2019s syndrome","volume":"43","author":"Sami","year":"2024","journal-title":"Clin Rheumatol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/mus.21197","article-title":"Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica","volume":"39","author":"McKeon","year":"2009","journal-title":"Muscle Nerve"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1423107\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T01:18:09Z","timestamp":1731979089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1423107\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":67,"alternative-id":["10.3389\/fimmu.2024.1423107"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1423107","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]},"article-number":"1423107"}}